Management of Subcentimeter Mediastinal Nodules on LDCT

Size-Based Management Algorithm

The American College of Radiology recommends no follow-up imaging for asymptomatic subcentimeter mediastinal lymph nodes (<10 mm in short axis) found incidentally on LDCT, as these are considered benign 1, 2
For nodes 10-15 mm, consider clinical context and associated pulmonary findings, and if explainable by benign conditions, no further workup is needed 1, 3
Nodes >15 mm require further evaluation with CT follow-up, FDG PET/CT, or biopsy depending on clinical context 1, 3
Nodes >25 mm are highly suspicious and typically pathologic 4, 5

The American College of Radiology suggests documenting short-axis diameter, texture/density, calcification pattern, and associated pulmonary findings when evaluating these nodules 1, 2, 3
Benign nodes typically show smooth borders, uniform attenuation, and central fatty hilum 3
Homogeneous calcification suggests inactive/benign disease 6

Young males with subcentimeter nodes should be maintained with higher suspicion for lymphoma or metastatic germ cell tumors, and consider FDG PET/CT if multiple nodes or concerning features are present 1, 2, 6
Patients with B symptoms (fever, night sweats, weight loss) warrant immediate FDG PET/CT regardless of node size 1, 2

Refer for clinical consultation or specialist evaluation if nodes are 15-25 mm without clear benign explanation, multiple enlarged nodes in young males, any systemic symptoms are present, nodes demonstrate loss of fatty hilum or irregular borders, or nodes show growth on follow-up imaging 1, 2, 6, 3, 5

Historically, a 10 mm cutoff has been used for mediastinal lymph nodes because nodes with short axis diameter >10 mm in normal subjects are rare, though the normal maximum can be up to 14 mm, as noted by the Thorax journal 7, 8
The sensitivity of CT for N-staging using size criteria is only 60-65%, with specificity of 60-70%, according to the Thorax journal 7, 8

For nodes measuring exactly 10 mm, clinical context becomes critical, as reported in the Thorax journal 7, 8
Patients with known extrapulmonary malignancy may require different evaluation thresholds, though validation of risk prediction models in this population is still needed, as stated in the Thorax journal 9